IFIH1 and interstitial lung disease: This importantly includes the inflammatory myopathies, especially “anti-synthetase syndrome” and “clinically amyopathic dermatomyositis”, which carry a substantially increased risk of ILD and high mortality and are identified by the presence of anti-synthetase or anti-CADM140/MDA5 antibodies and may be present in patients with apparent “idiopathic” ILD without ANA or anti-Jo1 antibodies on initial serological screening [35,43].